NYSE: INSPInspire Medical Systems Inc Stock
$150.21+3.30 (+2.25%)
Updated Apr 17, 2025
INSP Price
$150.21
Fair Value Price
N/A
Market Cap
$4.46B
52 Week Low
$123.00
52 Week High
$257.40
P/E
83.45x
P/B
6.46x
P/S
6.87x
PEG
2.44x
Dividend Yield
N/A
Revenue
$802.80M
Earnings
$53.51M
Gross Margin
84.7%
Operating Margin
7.28%
Profit Margin
6.7%
Debt to Equity
0.17
Operating Cash Flow
$130M
Beta
1.34
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
INSP Overview
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was founded in 2007 and is headquartered in Golden Valley, Minnesota.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INSP's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
INSP
Ranked#23 of 102
Ranked#23 of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.82 | A | |
| $22.79 | A | |
| $13.33 | A |
Be the first to know about important INSP news, forecast changes, insider trades & much more!
INSP News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INSP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INSP ($150.21) is trading above its intrinsic value of $31.08, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INSP is poor value based on its earnings relative to its share price (83.45x), compared to the US market average (27.98x)
P/E vs Market Valuation
INSP is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more INSP due diligence checks available for Premium users.
Valuation
INSP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
83.45x
Industry
41.14x
Market
27.98x
INSP is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INSP is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
INSP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.46x
Industry
3.8x
INSP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INSP price to earnings growth (PEG)
For valuing profitable companies with growth potential
INSP is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
INSP's financial health
Profit margin
Revenue
$239.7M
Net Income
$35.2M
Profit Margin
14.7%
INSP's Earnings (EBIT) of $58.48M... subscribe to Premium to read more.
Interest Coverage Financials
INSP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$808.4M
Liabilities
$118.7M
Debt to equity
0.17
INSP's short-term assets ($630.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INSP's short-term assets ($630.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INSP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INSP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$69.2M
Investing
$3.8M
Financing
-$70.1M
INSP's operating cash flow ($130.25M)... subscribe to Premium to read more.
Debt Coverage Financials
INSP vs Medical Device Stocks
Inspire Medical Systems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.